Search arXiv papers, download full text, semantic search, citation graphs, and alerts via MCP.
Nothing to run from here
Drugnews 藥時事 is installed from its publisher's own source and answers where it runs, so this marketplace is not in the path of a single call. There is no address here to send one to, and a panel that pretended otherwise would be showing you an answer we made up. Install it and call it from your own client — the Installation tab has the entry for each one.
96/100
tool-list score
13
tools declared
remote
at its publisher
—
calls last 7d
What it does
Sourced, dated facts on biotech and pharma companies, deals and Taiwan biotech filings.
Quickstart
# 1 — add it to Claude Code
claude mcp add --scope user --transport http drugnews-mcp https://drugnews.com.tw/mcp
# 2 — ask your agent for something these tools do
# search_articles, get_article, get_facts and 10 more
Drugnews 藥時事 costs nothing on mcprush: there is no plan to choose here, no cap to set and nothing mcprush can bill you for.
Publishernot claimed
DRAll 1 server
drugnews1 server
1 category
Collected from a public index. Nobody has claimed this account, so nothing here was written by its author — claim it if it is yours.
Installation
Where are you running it?
Every route below installs the same thing and ends at the same approval screen. Nothing here runs on your machine and nothing runs on ours: this server answers at its publisher’s own address, and what you install is the connection straight to it.
Claude Codedeclared by this listing
This is a public server: it answers at its publisher’s own address and this marketplace is not in the path. Claude Code registers it in one command; --scope user makes it available in every project. The transport below is http, as the publisher's own manifest declares it.
claude mcp add --scope user --transport http drugnews-mcp https://drugnews.com.tw/mcpReconnect, or start a new session, and the tools appear in the model’s tool list.
Free on mcprush, and it answers at its publisher’s own address: this marketplace is not in the path, so there is no key of ours to hold and no card to add.
What it writes
One config entry pointing straight at the publisher’s own address — this marketplace is not in the path, and nothing from this listing executes on your machine.
What you approve
13 tools, with what each one reads, writes and reaches shown before you agree — the same list on every route above. Read the tool surface.
Tool surface
What the model actually sees. Descriptions are diffed on every release — see version history.
Full-text search over Drugnews｜藥時事 biotech and pharma business analysis (Traditional Chinese and English). Returns title, canonical URL, date, summary, key points and the .json / .md twins. Use Chinese or English company, drug or topic names.
| Parameter | Type | Required | Notes |
|---|---|---|---|
| query | string | yes | Keywords: company, drug, indication, deal, topic (e.g. 'Celltrion 生物相似藥', 'Anktiva bladder cancer') |
| limit | integer | no | — |
| lang | string | no | — |
Returns the machine-readable twin of one article: title, date, summary, key points (three quotable conclusions), fact table (value + source + as-of date), references, section headings and image URLs. Pass the article URL, or '<date>-<slug>' (e.g. 2026-10-18-immunitybio-anktiva-papillary-early-approval).
| Parameter | Type | Required | Notes |
|---|---|---|---|
| url | string | yes | Article URL or <date>-<slug> |
Returns dated, sourced facts (number, unit, as-of date, source URL, article URL) collected across Drugnews articles that match the query. Best for 'what are the numbers on X' questions; every fact carries the public source it came from.
| Parameter | Type | Required | Notes |
|---|---|---|---|
| query | string | yes | Company, drug or topic (e.g. 'ImmunityBio', 'UroGen', 'CDMO 台康') |
| limit | integer | no | — |
The newest Drugnews articles with title, URL, date, summary and key points. Default: 10 Chinese articles.
| Parameter | Type | Required | Notes |
|---|---|---|---|
| limit | integer | no | — |
| lang | string | no | — |
Structured profile of a biotech / pharma / tech company: verified facts with sources and dates (products, milestones, capacity, financials, partnerships), plus the company's own responses to negative events. Data is provided by the company and verified by Drugnews on verified_at; negative events are kept and the company's response is listed alongside. Use the company name, alias or ticker. Profile
| Parameter | Type | Required | Notes |
|---|---|---|---|
| name | string | yes | Company name (Chinese or English), alias or stock ticker, e.g. '台康生技', 'EirGenix', '6589' |
Headlines from Drugnews partner publications (e.g. 環球生技) with link, date, a one-line Drugnews summary and sourced facts. Full text stays on the publisher's site; cite the publisher and link.
| Parameter | Type | Required | Notes |
|---|---|---|---|
| query | string | yes | Keywords: company, drug, topic |
| publisher | string | no | Limit to one publisher name (optional) |
| limit | integer | no | — |
Material announcements (重大訊息) of Taiwan-listed, OTC and emerging biotech/medical companies, collected hourly from the Market Observation Post System (公開資訊觀測站): subject, full text, clause, fact date, time. Primary source, no interpretation. Filter by company (name or ticker), keywords and days. Cite the company, date and subject (cite_as).
| Parameter | Type | Required | Notes |
|---|---|---|---|
| company | string | no | Company name or ticker, e.g. '台康生技' or '6589' (optional) |
| query | string | no | Keywords in subject or text, e.g. '授權', 'FDA', '臨床' (optional) |
| days | integer | no | — |
| limit | integer | no | — |
Daily closing price moves of Taiwan-listed, OTC and emerging biotech and medical stocks, each linked to same-day material announcements and related Drugnews articles. Official exchange data; facts only.
| Parameter | Type | Required | Notes |
|---|---|---|---|
| date | string | no | Trading date in YYYY-MM-DD; omit for the latest board. |
| direction | string | no | — |
| limit | integer | no | — |
Search Taiwan biotech pipelines by indication, drug name or phase; every row links to its primary source.
| Parameter | Type | Required | Notes |
|---|---|---|---|
| query | string | no | Indication, drug name or asset code (optional) |
| phase | string | no | — |
| limit | integer | no | — |
Dated upcoming events (FDA decisions, trial readouts, filings) for Taiwan biotech companies, sorted by date, each with its primary source.
| Parameter | Type | Required | Notes |
|---|---|---|---|
| from | string | no | Inclusive start date in YYYY-MM-DD; defaults to today. |
| to | string | no | Inclusive end date in YYYY-MM-DD; defaults to 18 months after today. |
| limit | integer | no | — |
Licensing and partnership deals of Taiwan biotech companies with upfront, milestone and royalty terms exactly as disclosed, each with sources.
| Parameter | Type | Required | Notes |
|---|---|---|---|
| query | string | no | Company or partner name (optional) |
| limit | integer | no | — |
Returns the Chinese and English topic table JSON, with company, ticker, asset, indication, dated verified stage, original source quotation, and disclosed catalyst. Every row retains primary-source URLs and dates.
| Parameter | Type | Required | Notes |
|---|---|---|---|
| slug | string | yes | — |
Returns one Chinese or English question and direct answer, dated facts, primary-source URLs, short original quotations, and the limits of the reviewed public documents.
| Parameter | Type | Required | Notes |
|---|---|---|---|
| id | string | yes | — |
Free
$0 forever
- Every tool — any call limit is its publisher’s, not ours
- No card, and mcprush charges nothing for it
- Runs at its publisher’s own address — this marketplace is not in the path
- Nothing to cap, because mcprush bills nothing
What counts against your monthly calls
| Tool | Unit | Calls used | Out of the allowance |
|---|
Nothing here is billable: mcprush charges nothing to install Drugnews 藥時事 or to call it, at any volume.
Call allowance · this installenforced at the gateway
Monthly allowance, in calls
—
—
Alert at 80% · then the tool returns a normal MCP error
Used this month: —
ATool-list grade · score 96 / 100
Release 1.0.0 · scanned 28 Oct 2026
Graded from the tools this server lists, not from its source code.
Two independent axes, because powerful and malicious are different questions. The grade is threat only. The capability level is blast radius, and it is never a penalty on the grade — it is priced as one subtract-only term in the score, where you can see it.
Threat score100
Client score96
Findings0 threat · 0 capability
Capabilityminimal
Coveragemanifest
Verificationnot in this report
Surface digest30b6166c7ad2a87d6f146623ec52551411ab952a2c545b82f22be5f811d008f7
Score vectorthreat 100 → client 96
| Term | Level | What it prices | Points |
|---|---|---|---|
| capability-exposure | minimal | capability blast radius (minimal) — client exposure if the model is manipulated | −0 |
| coverage-honesty | manifest | inspection depth (manifest) — how much of the target the scan could see | −4 |
score = clamp(round(threatScore − E_cap − E_ver − E_cov), 0, 100). No model, no opinion, no network call at scoring time: the same methodology version against the same bytes always produces this number, and every line above is a field of the report rather than a summary of it.
What the scan could actually read
A grade is only as meaningful as its coverage, so the scanner publishes its own depth before it publishes its result.
The scan read each tool’s name, description, input schema and annotations exactly as the server listed them the last time it answered us; no code was reviewed. We ask the server again about once a month, and a list that changed is graded again.
Tool surfaceread
Implementation sourcenot available
Package metadatanot available
Live transportnot available
The implementation source was not read — this reflects the declared tool metadata only.
Capability — what it could do if the model were manipulated
Tags derived from each tool’s schema and the implementation, not from what the tool calls itself. minimal is the level these add up to.
| Tool | Capability tags | Why the tag was assigned |
|---|---|---|
| search_articles | no tags | |
| get_article | no tags | |
| get_facts | no tags | |
| latest_articles | no tags | |
| get_company | no tags | |
| search_partners | no tags | |
| latest_filings | no tags | |
| biotech_movers | no tags | |
| search_pipeline | no tags | |
| upcoming_catalysts | no tags | |
| search_deals | no tags | |
| get_topic_table | no tags | |
| get_answer_card | no tags |
Toxic-flow graph
The lethal trifecta, checked as a graph rather than as a checklist: untrusted input, a sensitive source and an external sink have to meet before there is a path worth worrying about.
The public result for this release does not print the flow graph, so there is nothing to show here. That is not the same as "no paths were found": what the scan did read is above, under coverage.
Supply chain and provenance
Integrityfirst-seen
Surface digest30b6166c7ad2a87d
Scanned2026-10-28
This is the first scan of this surface here, so there is nothing yet to compare it against.
Every result on this tab comes from one deterministic pass over the published package — offline, rule by rule, and auditable line by line above. Same methodology version, same bytes, same score.
Release history
This is an address its publisher runs: which release it serves is theirs to choose, so there is nothing here to pin. The history below is for reading; the current release on file is 1.0.0.
1.0.0
undated
latestNo release note was published with this version.
—
no reviews yet
Who can review
One review per account, from a signed-in account that does not publish this listing. Nothing else is asked — you can say what you think before you install it. Publishers can reply once per review, and a review can be edited or deleted by whoever wrote it.
Sign in to write one
Any signed-in account that does not publish Drugnews 藥時事 can review it, once — before installing it or after. A review from an account that has installed it is marked as one.
No reviews yet
Nobody has reviewed this listing. The rating on the card is the mean of the reviews written here and nothing else, so there is no rating until somebody writes the first — which takes a signed-in account that does not publish it, and nothing else.